(1.02%) 5 099.96 points
(0.40%) 38 240 points
(2.03%) 15 928 points
(0.11%) $83.66
(-1.16%) $1.619
(0.30%) $2 349.60
(-0.43%) $27.52
(0.42%) $924.40
(0.32%) $0.935
(0.67%) $11.02
(0.13%) $0.800
(-0.07%) $92.11
@ $9.02
发出时间: 15 Feb 2024 @ 03:04
回报率: 37.03%
上一信号: Feb 14 - 22:30
上一信号:
回报率: 0.89 %
Live Chart Being Loaded With Signals
Nurix Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule therapies for the treatment of cancer and immune disorders...
Stats | |
---|---|
今日成交量 | 599 462 |
平均成交量 | 1.02M |
市值 | 733.16M |
EPS | $0 ( 2024-04-11 ) |
下一个收益日期 | ( $-0.720 ) 2024-07-11 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -4.65 |
ATR14 | $0.0200 (0.16%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-02-16 | Van Houte Hans | Sell | 6 812 | Common Stock |
2024-02-13 | Van Houte Hans | Buy | 150 000 | Employee Stock Option (right to buy) |
2024-02-13 | Van Houte Hans | Buy | 45 000 | Restricted Stock Units |
2024-02-13 | Ring Christine | Buy | 150 000 | Employee Stock Option (right to buy) |
2024-02-13 | Ring Christine | Buy | 45 000 | Restricted Stock Units |
INSIDER POWER |
---|
91.86 |
Last 100 transactions |
Buy: 2 499 418 | Sell: 108 263 |
音量 相关性
Nurix Therapeutics, Inc. 相关性
10 最正相关 |
---|
10 最负相关 |
---|
你知道吗?
相关性是描述两个变量之间关系的统计指标。它的取值范围为-1到1,其中-1表示完全负相关(一个变量增加,另一个变量减少),1表示完全正相关(一个变量增加,另一个变量也增加),0表示没有相关性(变量之间没有关系)。
相关性可用于分析任何两个变量之间的关系,而不仅仅是股票。它通常用于金融、经济学、心理学等领域。
Nurix Therapeutics, Inc. 相关性 - 货币/商品
Nurix Therapeutics, Inc. 财务报表
Annual | 2023 |
营收: | $76.99M |
毛利润: | $63.33M (82.26 %) |
EPS: | $-2.65 |
FY | 2023 |
营收: | $76.99M |
毛利润: | $63.33M (82.26 %) |
EPS: | $-2.65 |
FY | 2022 |
营收: | $38.63M |
毛利润: | $27.82M (72.02 %) |
EPS: | $-3.42 |
FY | 2021 |
营收: | $29.75M |
毛利润: | $0.00 (0.00 %) |
EPS: | $-2.64 |
Financial Reports:
No articles found.
Nurix Therapeutics, Inc.
Nurix Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule therapies for the treatment of cancer and immune disorders. The company develops NX-2127, an orally available Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally available Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications. It also develops NX-0255, a CBL-B inhibitor for ex vivo use to enhance adoptive T-cell therapy; and DeTIL-0255 that is in the Phase 1 clinical trial for the treatment of gynecologic cancers, including ovarian, endometrial, and cervical cancer. The company has a strategic collaboration agreement with Gilead Sciences, Inc. for cancer and other challenging diseases patients; and Sanofi S.A. The company was formerly known as Nurix Inc. and changed its name to Nurix Therapeutics, Inc. in October 2018. The company was incorporated in 2009 and is headquartered in San Francisco, California.
关于 实时信号
此页面上呈现的实时信号有助于确定何时购买或出售NA. 信号具有高达1分钟的延迟;与所有市场信号一样,存在误差或错误的可能性。
实时交易信号不是绝对的,getagraph.com 对基于这些信号采取的任何行动概不负责,如《使用条款》中所述。这些信号是基于广泛的技术分析指标。